Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo
about
Targeting TBP-Associated Factors in Ovarian CancerPrecision targeted therapy of ovarian cancerSrc Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regressionRapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.New insights on the role of hormonal therapy in ovarian cancerMAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.Recurrent epithelial ovarian cancer and hormone therapy.Lapatinib induces p27(Kip1)-dependent G₁ arrest through both transcriptional and post-translational mechanismsInhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.Cigarette Smoke Mediates Nuclear to Cytoplasmic Trafficking of Transcriptional Inhibitor Kaiso through MUC1 and P120-Catenin.Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
P2860
Q26866045-67F49242-6688-4BEE-9365-4C6E44CA22D3Q28078658-D3A6920B-0EBA-44D0-8142-FD3013F314F8Q30679405-2D221E7A-99DC-4927-8D56-D8130BB953B6Q33685402-A7EA9440-55EC-4903-8921-089E0F7CBE6AQ34022694-4173FA19-C6B0-48D7-85BC-12B3AAE4FA69Q35484712-61BAACF0-79BD-45D2-A414-87105A3B2C8CQ35659675-469A9676-D801-4529-8E92-9F7E707485BFQ36001247-21574BAD-EE76-4D31-BDF8-0329DF000B23Q36586093-91C5A008-9F0A-4A2D-8128-7F6FD966D9EFQ37354691-63E42031-E7EE-46CE-BB3C-4FEB61E680A6Q37396923-59AD2278-C2D3-491C-A1A6-FD2CDBE57C3DQ37493335-D5142BD4-8C63-44F9-85ED-B011801FC694Q37558633-395DB03A-8479-47DE-ACD7-E4FCA808C2ADQ37672753-C57FE21B-650F-4531-8293-079B282DBBE9Q38631373-799F36BA-6FDB-41C7-AC5F-D91675867F78Q39028384-69DB3086-AF2C-485E-A8C1-7D8E6501D044Q39263745-5EC37D33-B880-47EE-B25A-AC82F94CD86FQ39265329-5C796401-6E49-4770-8CB5-E16184567CD7Q50005441-5A69E538-842E-4AA9-B13F-CE559175BC37
P2860
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Src Inhibition with saracatini ...... er models in vitro and in vivo
@en
type
label
Src Inhibition with saracatini ...... er models in vitro and in vivo
@en
prefLabel
Src Inhibition with saracatini ...... er models in vitro and in vivo
@en
P2093
P2860
P1476
Src Inhibition with saracatini ...... er models in vitro and in vivo
@en
P2093
Ali Pedram
Brian Rabinovich
Candace A Gilbert
Ellis R Levin
Fiona Simpkins
Gordon B Mills
Isildinha M Reis
Ji-Yeon Yang
Joyce M Slingerland
P2860
P304
P356
10.1158/1078-0432.CCR-12-1257
P407
P577
2012-08-15T00:00:00Z